

Transplant Immunology II

Update for the therapeutics for acute renal transplant rejection.

Ian DITTMER

In this session we will review guidelines that have been issued by groups such as KDIGO and NKF and trial evidence that has been published in the interim. We will address both cell-mediated and antibody-mediated rejection.

This will include the initiation of enhanced immunosuppressive agents and the intensification of background immunosuppression. Suggested dosing regimens will be presented. The increased intensity of immunosuppression needs to be balanced around other medical issues such as co-morbidities and infection in the recipient.

We will address the need to introduce infectious prophylaxis. Suggestions for monitoring the effectiveness of the rejection treatment will be discussed.